Deals: Page 3
-
Getty Images
Adaptimmune, seeking to stay afloat, sells off cell therapies
A deal with US WorldMeds includes the FDA-approved TCR therapy Tecelra and two clinical-stage cancer medicines.
By Jonathan Gardner • July 28, 2025 -
Courtesy of GSK
China competitionGSK pays $500M to enter drugmaking alliance with Hengrui
The deal, which focuses first on a COPD drug GSK believes holds “best-in-class” potential, could involve a dozen medicines and be worth $12 billion.
By Ben Fidler • July 28, 2025 -
Getty Images
VaccinesSanofi to acquire vaccine biotech in billion-dollar deal
The French pharma will pay $1.15 billion upfront to buy Vicebio and gain access to non-mRNA vaccine candidates against RSV and metapneumovirus.
By Delilah Alvarado • Updated July 22, 2025 -
Dimensions via Getty Images
China competitionCancer drugmaker LaNova to sell to China’s Sino Biopharm
Sino Biopharmaceuticals plans to pay up to $950.9 million to acquire LaNova Medicines, which previously licensed drugs to Merck and AstraZeneca.
By Ned Pagliarulo • July 15, 2025 -
Jason Doiy via Getty Images
Patent thicketsWith Verona deal, Merck wagers on strength of lung drug’s patents
The main patent for Ohtuvayre, the COPD drug at the heart of Verona’s $10 billion sale, expired in 2020. For Merck to make good on the deal, other secondary patents will need to hold up.
By Jonathan Gardner • July 11, 2025 -
Alamy
Merck to buy Verona and its lung drug in $10B deal
The New Jersey-based pharma has inked one of the biggest deals of the year in pursuit of a promising new way to treat COPD.
By Kristin Jensen • July 9, 2025 -
Alamy
Immune resetAbbVie to buy CAR-T developer Capstan in deal worth up to $2.1B
The acquisition will expand AbbVie's exploration of in vivo CAR-T therapy, an ambitious approach that could sidestep some of the difficulties presented by current cell treatments.
By Ned Pagliarulo • June 30, 2025 -
Permission granted by Jen Randall / Kymera Therapeutics
Kymera adds Gilead as research partner, while advancing new candidate with Sanofi
The biotech will work on molecular glue degraders with Gilead in a new deal. Existing partner Sanofi changed its focus to a new drug prospect, meanwhile.
By Gwendolyn Wu • June 25, 2025 -
Scott Olson via Getty Images
Gene editingLilly to acquire Verve in $1B bet on gene editing for heart disease
The deal centers around a medicine that could “shift the treatment paradigm for cardiovascular disease,” Lilly said, but also follows a yearslong decline in Verve’s share price amid skepticism over the need for such a therapy.
By Kristin Jensen • June 17, 2025 -
Getty Images
Sage, following setbacks, to sell to Supernus for $561M
In what one analyst described as an “unremarkable” outcome, the brain drug developer is being acquired for just $8.50 per share, plus non-guaranteed additional payouts, after a series of stumbles that depressed its stock price.
By Delilah Alvarado • June 16, 2025 -
Courtesy of CureVac AG
BioNTech buys mRNA, courtroom rival CureVac in all-stock deal
Valued at $1.25 billion, the deal expands BioNTech’s cancer drug portfolio and heads off royalty costs it could have owed CureVac in ongoing patent litigation.
By Jonathan Gardner • June 13, 2025 -
Getty Images
Immune resetCullinan doubles down on bispecifics for autoimmune disease with Genrix deal
The deal gives Cullinan T cell engagers aimed at BCMA and CD19, which drugmakers are exploring as possible targets for antibody- and cell-based drugs for inflammatory conditions.
By Kristin Jensen • June 5, 2025 -
Getty Images
Lilly partners with Camurus in search of a long-lasting obesity drug
The deal, which could be worth up to $870 million overall, will give Lilly access to a delivery technology that may help extend the durability of up to four of its weight-loss medicines.
By Kristin Jensen • June 4, 2025 -
Courtesy of Sanofi
Sanofi to acquire Blueprint for up to $9.5B
The pharma giant is betting that Blueprint, whose research revolves around a certain kind of tyrosine kinase, will be a boost to its immunology business.
By Jacob Bell • June 2, 2025 -
Courtesy of Nwasinachi Adriana Ezeji/Center for Advanced Pain Studies, University of Texas, Dallas
Pain drugsLilly to buy pain drug developer SiteOne, challenging Vertex
The acquisition expands Lilly’s pain pipeline with a slate of drugs targeting ion channel proteins like NaV1.7 and NaV1.8.
By Jacob Bell • May 27, 2025 -
National Institute on Aging. (2017). "Beta-Amyloid Plaques and Tau in the Brain" [Image]. Retrieved from Flickr.
Sanofi gains experimental Alzheimer’s drug through Vigil buyout
Already a Vigil Neuroscience investor, Sanofi has agreed to buy the rest of the biotech’s shares for $8 apiece, representing a total deal value of $470 million.
By Jacob Bell • May 22, 2025 -
Permission granted by Pfizer
China competitionPfizer buys into PD-1/VEGF competition with 3SBio deal
Pfizer will pay China’s 3SBio $1.25 billion up front to access a cancer drug that could rival Akeso and Summit’s closely watched immunotherapy ivonescimab.
By Ben Fidler • May 20, 2025 -
Justin Sullivan via Getty Images
Regeneron wins bid to buy 23andMe out of bankruptcy
The biotech, which has for years invested in genetics research, plans to acquire "substantially all" of testing firm 23andMe's assets for $256 million.
By Ned Pagliarulo • May 19, 2025 -
Permission granted by PHIL
Sponsored by PHILBridging the data gaps that impact retail and specialty-lite success
Learn how to leverage predictive analytics and measure top KPIs to maximize patient outcomes, provider engagement and brand performance on this webinar from PHIL and Syneos Health.
May 19, 2025 -
Getty Images
BioMarin to buy rare disease drugmaker Inozyme for $270M
The deal “fits like a glove” for BioMarin’s business, according to an analyst who also thinks there could be a “valuable” market opportunity for Inozyme’s main drug.
By Jacob Bell • May 16, 2025 -
Getty Images
Obesity drugsNovo to work with Septerna in hunt for oral obesity drugs
The research collaboration, under which Septerna will receive more than $200 million in upfront and near-term fees, is the latest deal Novo has struck to expand its obesity pipeline.
By Gwendolyn Wu • May 14, 2025 -
Getty Images
GSK to buy liver disease drug for $1.2B
With its purchase of Boston Pharmaceuticals' drug, GSK extends a streak of dealmaking it's undertaken to build a liver disease franchise.
By Kristin Jensen • May 14, 2025 -
Spencer Platt via Getty Images
Facing ‘uncertainty on steroids,’ biotech dealmakers tread more cautiously
Experts say market turmoil has made it harder for buyers and sellers to agree on price, which can be an especially imposing obstacle to large acquisitions.
By Jacob Bell • May 6, 2025 -
Courtesy of Merck KGaA
Merck KGaA to buy biotech SpringWorks for $3.9B
The deal, which has been in the works for months, hands the German pharmaceutical company two approved drugs for rare tumors.
By Ned Pagliarulo • April 28, 2025 -
Courtesy of Sanofi
China competition
Sanofi licenses immune disease drugs from startup Earendil
The startup, affiliated with China-based antibody designer Helixon Therapeutics, is developing bispecific drugs aimed at multiple popular immune disease targets, such as TL1A and IL23.
By Kristin Jensen • April 17, 2025
Previous
